Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3.
D000192:Actinomycetales / Q000032:analysis; D000903:Antibiotics, Antineoplastic / Q000032:analysis* / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002460:Cell Line; D066246:ErbB Receptors; D006801:Humans; D006873:Hydroquinones / Q000032:analysis* / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011956:Receptors, Cell Surface / Q000378:metabolism*; D013055:Spectrophotometry, Infrared; D013056:Spectrophotometry, Ultraviolet
D000903:Antibiotics, Antineoplastic; D006873:Hydroquinones; D011956:Receptors, Cell Surface; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; C048212:erbstatin